Bone Biologics Corporation (BBLGW)

Market Cap	1.19M -48.2%
Revenue (ttm)	n/a
Net Income	-2.89M
EPS	-1.61
Shares Out	2.76M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,394
Open	5.39
Previous Close	6.54
Day's Range	5.39 - 12.00
52-Week Range	3.50 - 35.95
Beta	0.57
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About BBLGW

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or b...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 2
• Stock Exchange: Nasdaq
• Ticker Symbol: BBLGW
• Website: https://www.bonebiologics.com

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 15, 2026

Data Sources Report a data error